olaratumab   Click here for help

GtoPdb Ligand ID: 9172

Synonyms: IMC-3G3 | Lartruvo® | LY3012207
Approved drug
olaratumab is an approved drug (EMA & FDA (2016))
Compound class: Antibody
Comment: Olaratumab is a fully human anti-platelet-derived growth factor receptor α (PDGFRα) monoclonal antibody, developed by Eli Lilly (link to Lilly's olaratumab webpage here), originally developed by ImClone Systems, Inc. [2].
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with sequences 8 and 16 from patent US8128929, and directly to clone IMC-3G3 [1]. From patent US8128929 it appears that the epitope recognised by olaratumab overlaps the PDGFRα binding sites for PDGF-AA and PDGF-BB.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Soft tissue sarcoma (STS): Olaratumab plus doxorubicin was approved by the US FDA in October 2016, for patients with advanced STS. Additional clinical trials include Phase 1/2 NCT02659020 evaluating gemcitabine and docetaxel with or without olaratumab in patients with STS.
Other cancers: Phase 2 trials NCT01204710 (prostate cancer, plus mitoxantrone) and NCT00913835 (ovarian cancer, plus liposomal doxorubicin) have been completed. Paclitaxel plus carboplatin ± olaratumab in non-small cell lung cancer is in Phase 2 assessment. Recurrent glioblastoma multiforme and gastrointestinal stromal tumors (GIST) have also reached Phase 2 trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Coexpression of PDGFRα and PDGFs, consistent with autocrine-mediated growth, has been reported in sarcomas and glioblastomas. Hence PDGFRα antibodies are being developed to abbrogate aberrant PDGFRα signalling and uncontrolled proliferation in cancers expressing PDGFRα.
Eli Lilly have produced a mechanism of action video for olaratumab, which you can access here.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00913835 A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer Phase 2 Interventional Eli Lilly and Company
NCT01204710 A Study of Olaratumab (IMC-3G3) in Prostate Cancer Phase 2 Interventional Eli Lilly and Company
NCT02659020 A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Phase 1/Phase 2 Interventional Eli Lilly and Company
External links Click here for help